Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
Journal Information
Full Title: Cancer
Abbreviation: Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Disclosures Sarah M. Temkin reports consulting fees from Cancer Expert Now and payment or honoraria from Clovis Oncology outside the submitted work. Leigh M. Boehmer reports personal fees from Pfizer outside the submitted work. Leigha Senter reports personal fees and honoraria from AstraZeneca outside the submitted work. Destin R. Black reports payment or honoraria for the Ovarian Cancer Workshop to Willis‐Knighton Medical Center and participation on the Gynecologic Oncology Group Investigator Council outside the submitted work. Stephanie V. Blank reports research collaboration and institutional contracts with Glaxo Smith Kline, Roche, AstraZeneca, Seattle Genetics, Merck, AkesoBio, and NRG Oncology; participation on an Aravive data safety and monitoring board; and a leadership or fiduciary role with the Society of Gynecologic Oncology (unpaid), the American Board of Obstetrics and Gynecology, SHARE (unpaid), and the National Ovarian Cancer Coalition (unpaid) all outside the submitted work. Anna Yemelyanova reports personal fees and honoraria from Roche Diagnostics and meeting/travel support from AstraZeneca outside the submitted work. Anthony M. Magliocco reports honoraria from AstraZeneca, Roche, Merck, Bristol Myers Squibb, and Lilly; payment from the Department of Justice Office of the Inspector General for expert testimony; meeting/travel support from AstraZeneca; and is an employee of Protean BioDiagnostics and owns equity in the company all outside the submitted work. Mollie A. Finkel reports personal fees from AstraZeneca outside the submitted work. Premal H. Thaker reports institutional grants or contracts from AstraZeneca, Merck, Glaxo Smith Kline, Novocure, Aravive, and Clovis; personal fees from AstraZeneca, Glaxo Smith Kline, Stryker, Seagen, Celsion, Immunogen, and Aravive; honoraria from AstraZeneca, Merck, and Glaxo Smith Kline; payment for expert testimony; payment for participation on a data safety monitoring board or advisory board from Novocure, Glaxo Smith Kline, AstraZeneca, Celsion, Novocure, and Iovance; and owns stock options in Celsion all outside the submitted work. Matthew P. Smeltzer, Monique D. Dawkins, Tracy E. Moore made no disclosures."
"Funding Support Funding support from AstraZeneca and Merck was provided to the Association of Community Cancer Centers, and funding for medical writing support paid to Cactus Communications was contracted and compensated by AstraZeneca."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025